About

The ReViral team has an extensive track record in the discovery and development of antiviral therapies. We work closely with key collaborators and consultants to transform the lives of patients and families affected by life-threatening viral infections.

2011 - ReViral founded by members of the highly successful Arrow Therapeutics team, led by Dr Ken Powell (CEO) and Dr Stuart Cockerill (CSO)
2014 - Professor Raymond Schinazi joined the ReViral Board
2015 - ReViral announced US$21 million fundraising to advance clinical development of a novel antiviral drug
2016 - Dr Eddy Littler appointed as Chief Executive Officer
2017 - ReViral announced top-line safety and pharmacokinetics for RSV antiviral RV-521 in healthy volunteers
2018 - RV-521 completed a Phase 2a study in adult volunteers showing high potency and excellent safety

Board of Directors
Dr Ken Powell

Dr Ken Powell
Chairman

Dr Eddy Littler

Dr Eddy Littler
Chief Executive Officer

Dr. Raymond F. Schinazi

Dr. Raymond F. Schinazi
Non-Executive Director

Raphaël Wisniewski

Raphaël Wisniewski
Partner, Andera Partners

Chau Q. Khuong

Chau Q. Khuong
Private Equity Partner, OrbiMed

Isaac Manke

Isaac Manke
General Partner, New Leaf

Nanna Lüneborg

Nanna Lüneborg
Partner, Novo Ventures

Iain D. Dukes

Iain D. Dukes
Non-Executive Director

Management Team
Dr Ken Powell

Dr Ken Powell
Chairman

Dr Eddy Littler

Dr Eddy Littler
Chief Executive Officer

Dr Stuart Cockerill

Dr Stuart Cockerill
Chief Scientific Officer, Founder

Dr Rachel Harland

Dr Rachel Harland
Chief Operating Officer

Dr Neil Mathews

Dr Neil Mathews
Project Director, Founder

Max Herrmann

Max Herrmann
Chief Financial Officer

Dr Elaine Thomas

Dr Elaine Thomas
Head of Virology

Dr Seth Hetherington

Dr Seth Hetherington
Chief Medical Officer